Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Operations (2023 - 2025)

Immunome (IMNM) has disclosed Cash from Operations for 3 consecutive years, with 47953000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 14.01% year-over-year to 47953000.0, compared with a TTM value of 190919000.0 through Dec 2025, down 72.32%, and an annual FY2025 reading of 190919000.0, down 72.32% over the prior year.
  • Cash from Operations was 47953000.0 for Q4 2025 at Immunome, down from 40510000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 24173000.0 in Q1 2023 and bottomed at 53055000.0 in Q1 2025.
  • Average Cash from Operations over 3 years is 25773416.67, with a median of 28782000.0 recorded in 2024.
  • Peak annual rise in Cash from Operations hit 14.01% in 2025, while the deepest fall reached 374.98% in 2025.
  • Year by year, Cash from Operations stood at 17459000.0 in 2023, then crashed by 140.91% to 42060000.0 in 2024, then fell by 14.01% to 47953000.0 in 2025.
  • Business Quant data shows Cash from Operations for IMNM at 47953000.0 in Q4 2025, 40510000.0 in Q3 2025, and 49401000.0 in Q2 2025.